Intelligent Tissue Group (ITG), a biotechnology company based in Glasgow, has opened its Intelligent Clinical trials facility, with the intention of providing pharmaceutical, medical device and food manufacturing companies with resources to research the safety and effectiveness of new products. The new division (sited in the West of Scotland Science Park) will offer patient recruitment, trial management, study-visit assessments and collection of trial data.
Intelligent Clinical managing director Ellie Robertson told Outsourcing-Pharma that the addition of this new clinical trials facility enables ITG to provide end-to-end services for drug development clients.
“The Intelligent Tissue Group has a wealth of experience within the research sector through its existing companies, Tissue Solutions, and HistologiX," she said. “Extending our offering to include support for clinical trials means we can offer our clients a full service from pre-clinical development through to clinical trials.”
Robertson, with a history of working in clinical research, will be responsible for overseeing projects from clients around the world. The division plans to take on trials ranging from 40 to 5,000 patients globally, and it reportedly holds a database reach of more than 2.5m potential study participants within central Scotland.
“Intelligent Clinical has a unique study participant recruitment model which supports the rapid start-up of project; we have built a registry which allows easy identification of potential participants,” Robertson told us. “Within the private arena we are not time limited during the vital start-up phase with the need for NHS R&D approval resulting in months being cut from our timelines; this allows projects to progress in line with many other countries around the world.”
Morag McFarlane, ITG’s CEO and founding director, added, “The launch of Intelligent Clinical marks the latest milestone in our ambitious growth strategy. The company will both complement and enhance our current offering, sitting alongside Tissue Solutions and HistologiX, and will enable us to extend the range of highly specialised services we provide for our global client base.”
Ivan McKee, Scotland’s Minister for Trade, Investment and Innovation, said the establishment of Intelligent Clinical adds to the growth of the country’s life sciences industry.
“Collaborative partnerships like this demonstrate the range of specialist capabilities in the clinical trial process in Scotland and this latest enterprise will strengthen our reputation globally, as well as making a valuable and welcome contribution to the continued growth and success of the life sciences sector,” McKee said.